Modern anti-HIV therapy

Swiss Medical Weekly

Volumn 131, Issue 15-16, 2001, Pages 207-213

  Flepp, M ^a   Schiffer, V ^a   Weber, R ^a   Hirschel, B ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Anti HIV therapy; HAART; Protease inhibitor; Reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; DIDANOSINE; EFAVIRENZ; ERGOT ALKALOID; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CENTRAL NERVOUS SYSTEM DISEASE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; KIDNEY DISEASE; LIVER DISEASE; LONG TERM CARE; METABOLIC DISORDER; PATIENT COMPLIANCE; PATIENT MONITORING; SHORT SURVEY; SKIN DISEASE; TREATMENT INDICATION; VIRUS REPLICATION;

EID: 0035926061     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (30)

1. Impact of new anti-retroviral combination therapies in HIV-infected patients in Switzerland: Prospective multicenter study
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
3. Antiretrovirale HIV-Therapie: Empfehlungen 1998
4. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
5. Latent infection of CD4· T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
6. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
7. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
8. Prognosis in HIV-1 infection predicted by the quantity, of virus in plasma
9. Empfehlungen zur antiretroviralen HIV-therapie 2001
10. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
11. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations for the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
12. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
13. Severe ergotism associated with interaction between ritonavir and ergotamine
14. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits
15. Factors affecting adherence to antiretroviral therapy
16. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
17. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up
18. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the Viradapt Study
19. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
20. HIV-1-resistenz gegen antiretrovirale substanzen in der Schweiz
21. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
22. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
23. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
24. The Swiss-Spanish intermittent trial
25. Extended benefit of anti-HIV protease inhibitor-containing combination therapy through a dissociated viremia-CD4 T cell response
26. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
27. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy